Identification of Novel Oxazolo[5,4‐ d ]pyrimidines as IL‐33 Inhibitors for Immuno‐Oncology Therapy
ChemBioChem · 13.03.2026 · 27 (5)
DOI: 10.1002/cbic.202500417 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemBioChem, online erschienen am 08.03.2026. Verfasst von Younghoon Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Graduate School of Medical Science, Yonsei University, College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Interleukin-33, Pyrimidines, Antineoplastic Agents, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Ministry of Health and Welfare, National Research Foundation of Korea, Brain Korea 21 FOUR Project for Medical science, Yonsei University College of Medicine, Seoul, Republic of korea.
Abstract (Originalsprache)
The IL‐33/ST2 signaling axis plays a crucial role in shaping the tumor microenvironment, primarily by promoting immune suppression through tumor‐infiltrating regulatory T ( T reg ) cells. Elevated IL‐33 levels are associated with poor prognosis in multiple cancers, as IL‐33 enhances T reg stability, proliferation, and suppressive function, thereby dampening antitumor immunity. In this study, we present the rational design and biological evaluation of novel small‐molecule inhibitors targeting IL‐33/ST2 signaling to suppress T reg ‐mediated immune evasion. Guided by structure‐based drug design, we identified oxazolo[5,4‐ d ]pyrimidine derivatives capable of forming key hydrogen bonds within the IL‐33 binding pocket, thereby enhancing binding affinity. In vitro and ex vivo assays using T‐Cell Receptor(TCR)‐stimulated human T reg cells demonstrated that these compounds significantly suppressed IL‐33‐induced T reg activation and proliferation. Notably, KYH1942 showed the most potent activity, reducing IL‐33‐induced Foxp3 and Ki‐67 expression in a dose‐dependent manner, indicative of impaired T reg function. It is worth noting that the inhibitory activities of our compounds are comparable to that of a neutralizing ST2 antibody. To our knowledge, this is the first report demonstrating that small‐molecule IL‐33 blockade can directly suppress T regs , including IL‐33‐driven Foxp3 and Ki‐67 expression. These findings establish a novel immunotherapeutic strategy targeting IL‐33‐mediated immune suppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Graduate School of Medical Science, Yonsei University, College of Medicine, Seoul, Republic of Korea.
- Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea.
- Brain Korea 21 (BK21) FOUR Program, Yonsei Education & Research Center for Biosystems, Yonsei University, Seoul, Republic of Korea.
- Azcuris Co. Ltd., Sejong, Republic of Korea.
- College of Pharmacy, Korea University, Sejong, Republic of Korea.
- Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Sang-Jun Ha, Taebo Sim
Förderung
- Ministry of Health and Welfare
- National Research Foundation of Korea
- Brain Korea 21 FOUR Project for Medical science, Yonsei University College of Medicine, Seoul, Republic of korea
Zitieren
APA
Kim, Y., Hong, K. H., Ko, M., Kim, E., Ahn, B. G., Son, S., Jeon, Y. H., Ha, S. J., & Sim, T. (2026). Identification of Novel Oxazolo[5,4‐ d ]pyrimidines as IL‐33 Inhibitors for Immuno‐Oncology Therapy. ChemBioChem, 27(5). https://doi.org/10.1002/cbic.202500417
Vancouver
Kim Y, Hong KH, Ko M, Kim E, Ahn BG, Son S, et al. Identification of Novel Oxazolo[5,4‐ d ]pyrimidines as IL‐33 Inhibitors for Immuno‐Oncology Therapy. ChemBioChem. 2026;27(5). doi:10.1002/cbic.202500417
BibTeX
@article{Kim2026,
author = {Kim, Younghoon and Hong, Kyeong Hee and Ko, Minjoo and Kim, Eunji and Ahn, Bong-Geun and Son, Seyoung and Jeon, Young Ho and Ha, Sang-Jun and Sim, Taebo},
title = {Identification of Novel Oxazolo[5,4‐ d ]pyrimidines as IL‐33 Inhibitors for Immuno‐Oncology Therapy},
journal = {ChemBioChem},
year = {2026},
volume = {27},
number = {5},
doi = {10.1002/cbic.202500417}
}
EUVIMED